In a press release issued yesterday, Repros Therapeutics, Inc., has announced that it will be offering up to three million shares of its common stock to the public. The offering to the public is being made pursuant to an existing statement file with the Securities and Exchange Commission (SEC) and will be subject to market conditions that could potentially delay, prevent or otherwise impact the initial offering being made by Repros Therapeutics.
The book-running manager in this public offering of shares for Repros Therapeutics will be Bank of America Merrill Lynch with co-managers being Lazard Capital Markets LLC, Ladenburg Thalmann & Co. Inc. and Ascendiant Capital Markets, LLC. As the offer stands currently, Repros Therapeutics will grant underwriters a 30-day option to purchase up to an additional 15% of the number of shares sold.
Repros Therapeutics, Inc. is a Woodlands, Texas-based development stage biopharmaceutical company focused on the development of oral small molecule drugs for major unmet medical needs in male and female health. The company was founded in 1987 as Zonagen, and is currently most well-known for Androxal® – a Secondary HypoGonadism treatment for men, and Proellex® – for the treatment of uterine fibroids and endometriosis in women.